Faster aspart tied to better glycemic control than insulin aspart for gestational diabetes

Faster aspart, a fast-acting insulin aspart, has been approved in several countries for use in pregnancy. However, there needs to be more data related to outcomes in pregnancy, efficacy and safety in the Indian population (gestational diabetes women).

Against the above background, Aneesh Ghosh did a retrospective study to compare and evaluate the safety and efficacy of faster aspart and insulin aspart for managing gestational diabetes in pregnant women.

The conclusive study points are:

·The medical records of 60 pregnant gestational diabetes women were analyzed.

·These women were treated with faster aspart or insulin aspart at a tertiary care centre (March 2019 - September 2020).

·At four times of day, namely, fasting, 1 hour post breakfast, lunch and dinner,Self-monitored blood glucose (SMBG) levels recorded during six consecutive days any time before delivery were analyzed.

· In both groups, Pregnancy and neonatal outcomes were compared.

·Following dinner, the mean postprandial glucose (PPG) value was significantly lesser in the faster aspart group compared to the insulin aspart group (123.61± 2.52 mg/dL vs 125.87 ± 2.98 mg/dL)

·In the faster aspart group, women had significantly lower glycemic variability or fluctuations.

·In the faster aspart group, there was a Lesser number of hypoglycemic events recorded.

To conclude, better glycemic control is achieved with faster aspart compared to insulin aspart among women with gestational diabetes. The researchers warranted further studies on large-scale for validation of these outcomes.

Further reading:

GhoshAneesh*, Efficacy and Safety of Faster Aspart in Comparison to Insulin AspartAmong Indian Women with Gestational Diabetes, Current Diabetes Reviews 2023;19(): e221222212124 . https://dx.doi.org/10.2174/1573399819666221222154443